Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong ...

Strathcona Resources (OTCPK:STHRF) said Friday it formally launched its offer to acquire MEG Energy (OTCPK:MEGEF) that values ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

BMO Capital Markets reiterated its Outperform rating on Eli Lilly and Company (NYSE:LLY), setting a price target of $900 ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

LLY to acquire SiteOne for up to $1 billion. GSK's antibiotic study ends early for efficacy. MRNA loses H5 flu vaccine ...

Detailed price information for Bank of Montreal (BMO-N) from The Globe and Mail including charting and trades.

The acquisition grants Eli Lilly and Company (NYSE:LLY) access to SiteOne’s pipeline, including its lead compound currently in Phase 2 trials. Analyst Evan Seigerman of BMO described the ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock. LLY inks $1B deal to acquire SiteOne, adding phase II-ready pain drug STC-004 to ...